BFM
CKPT

Boothbay Fund Management’s Checkpoint Therapeutics CKPT Stock Holding History

Boothbay Fund Management’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,888
Closed -$34.8K – 1446
2024
Q4 		$34.8K Buy
+10,888
New +$36.9K ﹤0.01% 1397
2021
Q3 		– Sell
-1,463
Closed -$43K – 1924
2021
Q2 		$43K Buy
+1,463
New +$40.5K ﹤0.01% 1770

Other funds holding CKPT

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Boothbay Fund Management's CKPT Position: Q1 2025 in Review

Boothbay Fund Management sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 10,888 shares — an estimated $34.8K sold.

Boothbay Fund Management first reported a position in CKPT in Q2 2021 and held it in 2 quarters. The position peaked at $43K in Q2 2021. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

  • Boothbay Fund Management reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 10,888 Checkpoint Therapeutics shares in Q1 2025, an estimated $34.8K.
  • Boothbay Fund Management first reported a position in Checkpoint Therapeutics in Q2 2021 and held it in 2 quarters.
  • Boothbay Fund Management's Checkpoint Therapeutics position peaked at $43K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.